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Abstract
Serum indices can give valuable information and should be interpreted as a result. Lipaemia can influence results through different mechanisms, an 
important one being the electrolyte exclusion effect. A case of pseudohyponatraemia due to this is reported. A 15-year-old female with type 2 dia-
betes was seen for follow-up. Her biochemistry results revealed severe hyponatraemia of 118 mmol/L. Her capillary glucose concentration was 13.7 
mmol/L with a corrected sodium of 122 mmol/L. A lipaemic index of 3+ (absolute value 1320) was noted, which was not flagged by the laboratory 
information system, as it was below the critical lipaemia limit for sodium determination. Repeated analysis of the same sample using a direct ion 
selective electrode method, the serum sodium concentration was 134 mmol/L (sodium corrected for glucose = 138 mmol/L). A triglyceride concen-
tration was requested, which was severely raised (100.1 mmol/L). The electrolyte exclusion effect is an analytical phenomenon that causes falsely 
low electrolyte concentrations in the presence of severe lipaemia or hyperproteinaemia when using indirect analytical methods. These methods are 
used on many modern-day automated chemistry analysers and should be considered in a patient with asymptomatic hyponatraemia. 
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Hyponatraemia is an electrolyte abnormality that 
is frequently encountered in hospitalised patients 
(1). It is defined as a sodium concentration of < 135 
mmol/L and is often associated with an increased 
morbidity and mortality (2). The time of onset and 
cause of hyponatraemia will direct management. 
Therefore, diagnostic algorithms provide a step-
wise approach in identifying the cause of hy-
ponatraemia (2). An important factor is to incorpo-
rate clinical findings and other biochemical find-
ings when assessing a patient with hyponatrae-
mia. The initial step is to determine whether the 
hyponatraemia is in fact a “true” hypotonic hy-
ponatraemia that is in keeping with the patient’s 
clinical presentation.  
The initial biochemistry results often do not in-
clude serum osmolality, total protein or triglycer-
ide measurement, but assessing serum indices 
(haemolysis, icterus and lipaemia) could provide 
valuable information. In vitro haemolysis (evident 
by an increased haemolysis index) can cause a 
falsely low sodium concentration due to a dilu-
tional effect from the release of intracellular con-
tent (3). Lipaemic samples can cause interference 
in a variety of analytical tests through different 
mechanisms. An important mechanism of interfer-
ence is due to volume displacement, also known 
as the electrolyte exclusion effect, that affects 
electrolyte determination with indirect ion-selec-
tive electrode (ISE) potentiometry (4).  
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Case Report
Case and methods description
A 15-year-old girl attended the paediatric diabetes 
clinic of Tygerberg Hospital, Cape Town, South Af-
rica for a routine check-up. On presentation she 
was found to have faecal loading and mild diabetic 
ketoacidosis (DKA). She was known to have type 2 
diabetes mellitus (DM) since 2014, as well as non-
alcoholic fatty liver disease, overweight and meta-
bolic syndrome (DM, hypertension, and increased 
waist circumference, hypertriglyceridaemia and 
low high-density lipoprotein cholesterol). Manage-
ment included lifestyle modification, metformin, 
insulin, bezafibrate and enalapril, yet her glycaemic 
control remained suboptimal. Poor adherence to 
therapy was confirmed by the patient. Right sided 
abdominal pain and constipation were her only 
presenting complaints. On physical examination 
she was not dehydrated or shocked. Acanthosis ni-
gricans was noted. Lipohypertrophy, eruptive xan-
thomata or lipaemia retinalis were not detected. 
Her body mass index (BMI) was 26.0 kg/m2 (95th 
percentile on UK BMI chart). Abdominal examina-
tion revealed an enlarged liver (3 cm from the cos-
tal margin in midclavicular line) and palpable fae-
ces. The rest of the examination was unremarkable. 
The capillary blood glucose concentration was 22.1 
mmol/L (FreeStyle Optium Neo, Abbott, Doncaster, 
Australia), the β-hydroxybutyrate concentration 
was 3.7 mmol/L (FreeStyle Optium Neo, Abbott, 
Doncaster, Australia).  Urinalysis showed 4+ glyco-
suria and 4+ ketonuria (RightSign, Biotest, China). 
Additionally, urea, creatinine and a venous blood 
gas were requested. A venous blood gas could not 
be performed due to severe lipaemia. The blood 
was collected in a capillary for blood gas analysis 
which on visual inspection appeared clogged with 
severely turbid content and was therefore thought 
not suitable for analysis. The point of care 
β-hydroxybutyrate determination may be affected 
by triglyceride concentrations greater than 21.2 
mmol/L (5). A mild DKA was diagnosed on the ba-
sis of hyperglycaemia > 11 mmol/L, β-hydro xy-
buty rate concentration > 3 mmol/L and ketonuria 
(6). The patient was treated with hourly subcutane-
ous insulin and recovered speedily. 
Biochemical analysis was performed on a Roche 
Cobas 6000 analyser (Roche Diagnostics, Mannhe-
im, Germany). Sodium concentration was deter-
mined by indirect ISE potentiometry. The triglycer-
ide concentration was determined by an enzymat-
ic colorimetric method. Osmometry was per-
formed on an Advanced® Micro-Osmometer Mod-
el 3320 (Advanced instruments, Inc., Massachu-
setts, USA) using freeze point depression. The 
blood gas analyser was an ABL80 FLEX (Radiome-
ter Medical ApS, Denmark) using a direct ISE meth-
od for electrolyte determination. The Roche Cobas 
6000 analyser detects lipaemia using spectropho-
tometry. The lipaemia index has a semi-quantita-
tive measuring range of 10 to 2000. The method 
uses diluted samples (with 0.9% sodium chloride) 
to measure absorbances at two different wave-
lengths for each analyte. The primary wavelength 
for lipaemia is 660 nm and secondary wavelength 
700 nm (7). 
Informed consent was obtained from the patient 
and her mother. The Health Research Ethics Com-
mittee of Stellenbosch University, Cape Town 
(South Africa) approved this case report (C18/05/011).
Laboratory analyses
Table 1 shows the patient’s biochemistry results 
on the first day of admission. Her sodium concen-
tration on admission was 116 mmol/L (sodium cor-
rected for a glucose of 22.1 mmol/L was 123 
mmol/L) with a semi-quantitative lipaemic index 
of 1661 (8). As the lipaemic index was below the 
instrument alert level of 2000, this result was not 
flagged by the laboratory information system (LIS). 
The treating paediatrician was contacted, because 
the sodium was critically low. The paediatrician 
was informed that pseudohyponatraemia was sus-
pected in the light of the high lipaemic index, but 
the sample was insufficient for further investiga-
tions. The biochemistry tests were repeated on 
the same day, which again revealed a critically low 
sodium concentration of 118 mmol/L and semi-
quantitative lipaemic index of 1320. The capillary 
blood glucose was 13.7 mmol/L and therefore, the 
corrected sodium was 122 mmol/L. After high-
speed centrifugation, the sodium concentration of 
the infranatant was 128 mmol/L. The sodium con-
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centration was also determined by direct ISE on a 
blood gas analyser, which was 134 mmol/L (sodi-
um corrected for glucose of 13.7 mmol/L, was 138 
mmol/L). The measured serum osmolality was 303 
mmol/kg, with a calculated osmolarity of 269.9 
mmol/L (calc osmo = 2 x Na+ + Urea + Glucose). 
This revealed an increased osmolal gap of 33.1 
mmol/L (osmolal gap = measured osmolality – cal-
culated osmolarity) (9). The triglyceride concentra-
tion was extremely high, with a concentration of 
100.1 mmol/L after a 1:50 dilution. Acute pancrea-
titis was excluded as the lipase level was only mild-
ly elevated and the patient did not have symp-
toms suggestive of acute pancreatitis. 
What happened?
We describe a case of pseudohyponatraemia sec-
ondary to severe hypertriglyceridaemia in a pa-
tient with uncontrolled type 2 DM presenting with 
a mild DKA. The patient had severe hyponatrae-
mia which was not solely due to hyperglycaemia 
causing osmotic movement of water from the in-
tracellular space to the extracellular space (10). She 
had no signs or symptoms suggestive of severe 
hyponatraemia. The patient had a slight increase 
in measured serum osmolality, which could be 
due to hyperglycaemia and mild ketonaemia 
(11,12). Turhan et al. described that lipaemia did 
not significantly affect the measurement of serum 
osmolality (13). However, in our patient, the calcu-
lated serum osmolarity was significantly lower 
than the measured osmolality, which led to a high 
osmolal gap. This is due to calculated serum os-
molarity being susceptible to lipaemia interfer-
ence due to its effect on sodium determination 
when using indirect ISE (13). The analytical inter-
ference was overcome by using an alternative 
method (direct ISE) for sodium determination.
Discussion
Dyslipidaemia is common in individuals with type 
2 DM, with hypertriglyceridaemia being the most 
Analyte Admission Follow up (same day) Reference interval
Sodium, mmol/L (indirect ISE) 116 118
136 - 145Sodium infranatant, mmol/L (indirect ISE) 128
Sodium, mmol/L (direct ISE) 134
Potassium, mmol/L Haemolysis Haemolysis 3.5 - 5.1
Urea, mmol/L 3.8 1.4 - 5.4
Creatinine, mmol/L 53 39 - 85
Triglycerides, mmol/L 100.1 < 1.7 (fasting)
Amylase, U/L 30 19 - 76
Lipase, U/L 35 4 - 29
Indices
Haemolysis 113 (1+) 100 (1+)
Icterus 2 (1+) 2 (1+)
Lipaemia 1661 (4+) 1320 (3+)
Osmolality, mmol/kg 303 275 - 295
Point of care testing
Glucose, mmol/L 22.1 13.7 3.3 - 5.6
β-hydroxybutyrate, mmol/L 3.7 2.1 < 0.6
ISE - ion-selective electrode potentiometry.
Table 1. Patient’s biochemistry results on admission and at the follow up
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common lipid abnormality (14). Hypertriglyceri-
daemia is an independent risk factor for the devel-
opment of cardiovascular disease, acute pancreati-
tis (at triglyceride concentration > 10mmol/L) and 
is also an important endogenous interferent in 
laboratory analysis (4,15-17). 
Lipaemia is defined as the presence of high con-
centrations of lipoproteins in serum. A study per-
formed in an academic centre in Iowa reported 
that the most common causes of lipaemia were 
due to type 2 DM and iatrogenic secondary to the 
infusion of intravenous lipid emulsions (e.g. total 
parenteral nutrition) (18). The time of blood sam-
pling is also important, as sampling soon after a 
meal or after administration of lipid emulsions 
may increase the triglyceride content in serum (19). 
Lipaemia may cause interference in the analysis of 
many analytes, including albumin, electrolytes, 
lactate dehydrogenase, amylase and bilirubin (16). 
The semi-quantitative lipaemic index for interfer-
ence of lipase analysis is 2000, whereas it can 
cause a false decrease in amylase levels above a 
semi-quantitative lipaemic index of 1500 and is 
important to consider when assessing patients 
with hypertriglyceridemia for possible acute pan-
creatitis (20). Therefore, a lipase would be a more 
suitable test, as it has less interference due to li-
paemia and is also more specific for pancreatic in-
jury (20–22). 
The electrolyte exclusion effect may affect electro-
lyte concentrations when determined by indirect 
ISE or flame photometry methods. These methods 
involve a dilution step prior to analysis. Normal se-
rum consists of 93% aqueous phase and 7% solids 
(2). This ratio is disturbed in the serum of patients 
with significant lipoprotein abnormalities, causing 
an increase in the solid phase fraction. A fixed vol-
ume of diluent is used during this method and 
leads to a higher dilution due to the change in the 
solid phase fraction (2). There are different ways to 
overcome this interference, the easiest of which is 
to repeat analysis with a direct ISE method. Elec-
trolyte determination by this method is not affect-
ed by the electrolyte exclusion effect, because 
there is no dilution step prior to analysis. Bedside 
electrolyte analysers, including blood gas analys-
ers use direct ISE method (23). However, a study by 
Sen et al. demonstrated that even direct ISE meth-
ods may be affected by lipaemia (24). They dem-
onstrated a decline of 5.17% and 9.98% in the so-
dium concentrations determined on two different 
analysers using direct ISE. This study was conduct-
ed using Intralipid® and the finding should be con-
firmed in native hyperlipidaemic samples.
Another method to decrease lipaemia interfer-
ence is through ultracentrifugation, but this equip-
ment is not readily available in many laboratories 
(25). We attempted high-speed centrifugation of 
the sample and repeated analysis using indirect 
ISE potentiometry. The result obtained after high-
speed centrifugation (128 mmol/L) was lower than 
the result obtained by direct ISE (134 mmol/L) and 
was therefore not an effective method to decrease 
lipaemia interference in this case. Extraction of li-
poproteins through the addition of Lipoclear® (li-
poprotein precipitation) is an additional method 
to decrease the interference due to lipaemia, but 
may also interfere with sodium determination 
(19,26). However, in our laboratory, we do not have 
ultracentrifugation or Lipoclear® available and if 
pseudohyponatraemia is suspected, we repeat the 
analysis using direct ISE.
Lipaemia can also cause interference with spectro-
photometric methods due to the ability of lipo-
proteins to cause light scattering that may inter-
fere with nephelometric or turbidimetric methods 
(4,16). Partitioning of analytes is another mecha-
nism of interference leading to the movement of 
non-polar analytes (lipophilic analytes) into large 
non-polar lipoprotein particles, such as chylomi-
crons and very low density lipoproteins (16). This 
mechanism of interference should be considered 
when ultracentrifugation with removal of the lipid 
layer is performed, because this could lead to 
falsely low concentrations of analytes that are dis-
tributed in the lipid layer (19).
Visual inspection of samples was used for many 
years to detect lipaemia in serum samples (19). 
However, this method is time consuming and has 
wide inter-interpreter variability (27). With the in-
troduction of automated pre-analytical systems, 
sample handling by technologists has been re-
duced and automated detection of serum indices 
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became a vital part of laboratory diagnostics. The 
measurement of serum indices will improve re-
porting of results, which will have a direct effect 
on patient care. Management based on falsely low 
or elevated results due to endogenous interfer-
ences may lead to serious patient harm. 
Serum indices are often included in laboratory re-
ports at no additional cost to the patient and it is 
important that these indices are interpreted by the 
clinician. Unfortunately, many clinicians do not ap-
preciate the importance of indices and how they 
affect laboratory results. Serum indices give valua-
ble information on sample quality and may also 
give information about underlying conditions. In 
this case, the high lipaemic index alerted the clini-
cian to after-request triglyceride concentrations. It 
is important to note that there is no direct correla-
tion between the level of lipaemia and triglyceride 
concentration, because lipoproteins contain varia-
ble amounts of triglycerides (19). 
As indices are determined by analysers at various 
wavelengths, cross-interference should also be 
considered when interpreting results. The haemol-
ysis index is influenced by the degree of lipaemia 
due to the spectral-overlap of haemoglobin and 
lipaemia (28). The wide absorbance spectrum of li-
paemia between 300 to 700 nm can contribute to 
the absorbance of haemoglobin, which is meas-
ured at 415 nm on the Roche Cobas 6000 (4,29). 
This cross-interference between serum indices can 
lead to inappropriate rejection of results. However, 
many new automated analysers are introducing 
correction factors to try and prevent this (30).
The LIS middleware rules need to be set up appro-
priately to flag results that may have been affected 
by lipaemia (and other serum indices) and cross-
interference between indices. This will alert labo-
ratory staff of the interference and allow them to 
implement actions to decrease the interference 
and to account for cross-interference before the 
result is transmitted to the LIS. Our patient’s sodi-
um result was not flagged by the middleware and 
was transmitted to the LIS, because the current 
rule for lipaemia interference in sodium determi-
nation is set at a semi-quantitative index of 2000. 
This rule was set up according to the interference 
limitations specified in the package insert of the 
manufacturer (30). Roche accepts +/- 10% as the 
maximum allowable bias due to lipaemia for sodi-
um determination. If we accept 134 mmol/L as the 
patient’s true sodium result that was determined 
on the blood gas analyser, this means that the ac-
ceptable lower limit due to lipaemia interference is 
120.6 mmol/L (134 mmol/L - 10%). Our patient’s 
sodium concentration was 118 mmol/L, which is 
outside this lower limit at a semi-quantitative li-
paemic index of 1320. Also, the difference be-
tween the true sodium value (134 mmol/L) and 
the maximum allowable lower bias limit (120.6 
mmol/L) has significant clinical implications. This 
will change the severity of the patient’s hypona-
traemia from mild to profound. Furthermore, this 
acceptance criteria for lipaemia interference is 
much greater than the desirable specifications for 
total allowable error of 0.73% according to West-
gard (31). Therefore, the cut-off for lipaemia inter-
ference for sodium determination on the Roche 
Cobas analyser should be decreased from the cur-
rent recommendation of 2000. The use of a +/- 
10% maximum allowable bias due to lipaemia is 
not appropriate for sodium and the allowable bias 
should also take the biological variation, analytical 
variation and clinical implications into account. 
The interference thresholds set by manufacturers 
should be used with caution. Interference studies 
are often performed using Intralipid-spiked sam-
ples. The effect of Intralipid on certain analytes 
may differ from the effect of native lipaemia and 
therefore, it is recommended that lipaemic patient 
samples should be used for interference testing 
(32). A recent publication by von Meyer et al. urges 
manufacturers to improve the information on se-
rum indices interference that is provided (28). 
In conclusion, the electrolyte exclusion effect is an 
analytical phenomenon that causes falsely low 
electrolyte concentrations in the presence of se-
vere lipaemia or hyperproteinaemia when using 
indirect analytical methods. This method is used 
on many modern-day automated chemistry ana-
lysers and should be considered in a patient with 
asymptomatic hyponatraemia. This case demon-
strated the importance of routine reporting of se-
rum indices and its role in patient care. Lipaemia is 
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an important pre-analytical factor that influences 
the analytical phase in various ways. 
What YOU should / can do in your 
laboratory to prevent such errors
•	 The thresholds for endogenous interferents de-
termined by manufacturers should be used 
with caution when setting up algorithms on 
middleware. 
•	 Lipaemia interference and its cross interference 
with other indices should be identified accu-
rately by middleware rule-based algorithms (4).
•	 Appropriate analyte-specific management 
strategies should be in place to decrease the ef-
fect of lipaemia on results.
•	 Measurement of sodium concentration using a 
direct ISE method may overcome the electro-
lyte exclusion effect.
•	 Clinicians must appreciate the importance of 
serum indices and how they affect laboratory 
results.
•	 Reflex testing of triglycerides could be consid-
ered in patients with a high lipaemic index.
•	 Venous blood sampling should be performed 
after a 12 hour fasting period in non-emergen-
cy situations (33). 
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